ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå : Áö¿ªº°(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«) - ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2031³â)
Circadian Rhythm Sleep Treatment Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
»óǰÄÚµå
:
1470686
¸®¼Ä¡»ç
:
Persistence Market Research
¹ßÇàÀÏ
:
2024³â 04¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 310 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀåÀº ¼ö¸é Àå¾Ö¿¡ ´ëÇÑ ÀνÄÀÇ Áõ°¡¿Í ¼ö¸é ÀÇÇÐÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ºü¸£°Ô ¹ßÀüÇϰí ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â »ýü½Ã°è ±³¶õ¿¡ ´ëóÇϱâ À§ÇØ °í¾ÈµÈ ´Ù¾çÇÑ Ä¡·á¹ý°ú ¿ä¹ýÀÌ Æ÷ÇԵǸç, ÀÌ´Â ¼ö¸é°ú °¢¼º ÁÖ±â ¹× Àü¹ÝÀûÀÎ °Ç°¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÀÌ º¸°í¼´Â 2024³âºÎÅÍ 2031³â±îÁö ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀåÀÇ ¼ºÀå µ¿ÀÎ, ÀáÀçÀû °úÁ¦, »õ·Î¿î µ¿ÇâÀ» Á¶»çÇÏ¿© ÀÌÇØ°ü°èÀÚ ¹× ÀÇ·á Àü¹®°¡¿¡°Ô ±ÍÁßÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
¼¼°è ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ²ÙÁØÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³âºÎÅÍ 2031³â±îÁö 4.7%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀåÀº 2024³â 7¾ï 8,400¸¸ ´Þ·¯¿¡¼ 2031³â ¸»¿¡´Â 11¾ï ´Þ·¯·Î È®´ëµÉ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
ÃßÁ¤ ½ÃÀå °¡Ä¡(2024³â) : 7¾ï 8,400¸¸ ´Þ·¯
¿¹»ó ½ÃÀå °¡Ä¡(2031³â) : 11¾ï ´Þ·¯
¼¼°è ½ÃÀå ¼ºÀå·ü(2024-2031³â CAGR) : 4.7%
ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå - º¸°í¼ ¹üÀ§:
ÀÏÁֱ⠸®µë ¼ö¸éÀå¾Ö(CRSD)´Â Çö´ëÀÎÀÇ »ýȰ½À°ü º¯È¿Í Àΰø±¤¿¡ ´ëÇÑ ³ëÃâ Áõ°¡·Î ÀÎÇØ ÀÚ¿¬½º·¯¿î ¼ö¸é°ú °¢¼º Áֱ⿡ ¿µÇâÀ» ¹ÌÄ¡¸ç Á¡Á¡ ´õ ÈçÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àå¾Ö¿¡´Â ¼ö¸é ´Ü°è Áö¿¬ Àå¾Ö(DSPD), °íµµ ¼ö¸é ´Ü°è Àå¾Ö(ASPD), ±³´ë ±Ù¹« Àå¾Ö, ½ÃÂ÷ Àå¾Ö µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ º¸°í¼¿¡¼´Â ±¤Ä¡·á, ¸á¶óÅä´Ñ º¸ÃæÁ¦, Çൿġ·á, ¾à¸®ÇÐÀûÀÎ Á¢±Ù¹ý µî ´Ù¾çÇÑ Ä¡·á¹ýÀ» ´Ù·ç¸ç, ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ ¹üÀ§¿¡ ´ëÇØ Á¶»çÇÕ´Ï´Ù.
½ÃÀå ÃËÁø¿äÀÎ:
ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¼ö¸é °Ç°ÀÇ Á߿伺°ú Àü¹ÝÀûÀÎ À£ºù¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö´Â °ÍÀÌ Áß¿äÇÑ ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, Çö´ëÀÎÀÇ ¶óÀÌÇÁ½ºÅ¸ÀÏ, ½ºÆ®·¹½º, ¾÷¹« °ü·Ã ¿äÀÎÀ¸·Î ÀÎÇÑ ¼ö¸é Àå¾ÖÀÇ À¯º´·ü Áõ°¡´Â È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¼ö¸é ±â¼ú°ú °³ÀÎ ¸ÂÃãÇü ÀÇ·áÀÇ ¹ßÀüÀº º¸´Ù Á¤È®ÇÑ Áø´Ü°ú ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ýÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ¼ö¸é ÃßÀû ÀåÄ¡¿Í ¸ð¹ÙÀÏ °Ç° ¾ÖÇø®ÄÉÀ̼ÇÀÇ º¸±Þ È®´ë´Â ¼ö¸é Àå¾Ö¿¡ ´ëÇÑ Àνİú °ü¸®ÀÇ Çâ»ó¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¾ïÁ¦¿äÀÎ:
¼ºÀå ÀáÀç·ÂÀÌ ÀÖ´Â ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀåÀº ¸î °¡Áö µµÀü°úÁ¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀϺΠġ·á¹ý, ƯÈ÷ °íµµÀÇ ±â¼úÀ̳ª °³º°ÈµÈ Á¢±Ù¹ýÀ» ÇÊ¿ä·Î ÇÏ´Â Ä¡·á¹ýÀº ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ º¸±ÞÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀϺΠÁö¿ª¿¡¼´Â Àü¹® ¼ö¸é Ŭ¸®´Ð°ú Àü¹®°¡¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑÀûÀ̶ó´Â Á¡µµ ½ÃÀå ¼ºÀåÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÏÁֱ⠸®µë Àå¾Ö¿¡ ´ëÇÑ ÀϹÝÀÎÀÇ ÀÎ½Ä ºÎÁ·Àº Á¶±â Áø´Ü ¹× Á¶±â Ä¡·á¸¦ ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾à¸®ÇÐÀû Ä¡·áÀÇ ÀáÀçÀû ºÎÀÛ¿ë°ú ¼ö¸é º¸Á¶Á¦¿¡ ´ëÇÑ ÀÇÁ¸¼º¿¡ ´ëÇÑ ¿ì·Áµµ ¼ÒºñÀÚÀÇ ½Å·Ú¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ:
ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀåÀº ¸¹Àº Çõ½Å°ú È®ÀåÀÇ ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ±â¾÷µéÀº ±¤ Ä¡·á ±â±â ¹× ¼ö¸é ÃßÀû ¿þ¾î·¯ºí°ú °°ÀÌ º¸´Ù Á¢±ÙÇϱ⠽±°í Àú·ÅÇÑ Ä¡·á ¿É¼ÇÀ» °³¹ßÇÏ´Â µ¥ ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼ö¸é Àü¹®°¡¿Í ±â¼ú ±â¾÷ÀÇ °øµ¿ ³ë·ÂÀº º¸´Ù ÅëÇÕÀûÀÌ°í »ç¿ëÀÚ Ä£ÈÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á¿Í °¡»ó Áø·áÀÇ ºÎ»óÀº ƯÈ÷ ¿ø°ÝÁö¿¡¼ ¼ö¸é Ä¡·á ¼ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ¼ö¸é °Ç°¿¡ ´ëÇÑ ´ëÁßÀÇ ÀÎ½Ä Á¦°í Ä·ÆäÀÎÀÇ Áõ°¡´Â Á¶±â Áø´ÜÀ» ÃËÁøÇÏ°í ¿¹¹æ Á¶Ä¡¸¦ Àå·ÁÇÏ¿© ±Ã±ØÀûÀ¸·Î ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå ¼Ò°³
½ÃÀå ¹üÀ§/ºÐ·ù
½ÃÀå Á¤ÀÇ/¹üÀ§/Á¦ÇÑ
Á¦3Àå ¼¼°èÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä µ¿Çâ
½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä µ¿Çâ
Á¦Ç° Çõ½Å µ¿Çâ
Çõ½Å°ú ½ÅÁ¦Ç°
Áö¿ªº° Áúº´ °³¿ä¿Í ¿ªÇÐ(À¯º´·ü µ¥ÀÌÅÍ)
Á¦4Àå ¼¼°èÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå Çٽɼº°ø¿äÀÎ
Á¦Ç° ä¿ë/ÀÎÁöµµ ºÐ¼®
Á¦Ç° ±â´É°ú Àå¾Ö ¸ÅÆ®¸¯½º
Á¦5Àå ¼¼°èÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå - °¡°Ý ºÐ¼®
Áö¿ªº° °¡°Ý ºÐ¼®
°¡°Ý ³»¿ª
Á¦Á¶¾÷ü ·¹º§ °¡°Ý ¼³Á¤
À¯Åë¾÷ü ·¹º§ °¡°Ý ¼³Á¤
¼¼°è Æò±Õ °¡°Ý ºÐ¼® º¥Ä¡¸¶Å©
Á¦6Àå ¼¼°èÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå ¼ö¿ä ºÐ¼®°ú ¿¹Ãø
°ú°Å ½ÃÀå ±Ý¾×(±Ý¾×) ºÐ¼®,2019-2023³â
ÇöÀç ¹× ÇâÈÄ ½ÃÀå ±Ý¾×(±Ý¾×) ¿¹Ãø, 2024-2031³â
Àü³âºñ ¼ºÀå µ¿Ç⠺м®
Á¦7Àå ¼¼°èÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå »óȲ
ÁÖ¿ä ±ÔÁ¦
°Å½Ã°æÁ¦ ¿äÀÎ
¿¹Ãø¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀÎ
¼ºÀå ¾ïÁ¦¿äÀÎ
±âȸ ºÐ¼®
Á¦8Àå ¼¼°èÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå ºÐ¼®°ú ¿¹Ãø, Ä¡·á À¯Çüº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(±Ý¾×)¿Í ¼ö·® ºÐ¼®,2019-2023³â
½ÃÀå ±Ô¸ð(±Ý¾×)¿Í ¼ö·® ¿¹Ãø, 2024-2031³â
µð¹ÙÀ̽º
Ä¡·á ±â±â
¶óÀÌÆ® ¹Ú½º
µ¥½ºÅ© ·¥ÇÁ
¶óÀÌÆ® ¹ÙÀÌÀú
»õº® ½Ã¹Ä·¹ÀÌÅÍ
Áø´Ü Àåºñ
¾×Ƽ±×·¡ÇÇ ¼¾¼
¼Õ¸ñ°ú ¼Õ ¹êµåÇü ¾×Ƽ±×·¡ÇÇ Àåºñ
¿þ¾î·¯ºí ¾×Ƽ±×·¡ÇÇ µð¹ÙÀ̽º
¼ö¸é´Ù¿ø°Ë»ç Àåºñ
°íÁ¤½Ä ¼ö¸é´Ù¿ø°Ë»ç Àåºñ
ÈÞ´ë¿ë ¼ö¸é´Ù¿ø°Ë»ç Àåºñ
¾à¹°
º¥Á¶µð¾ÆÁ¦ÇÉ
ºñº¥Á¶µð¾ÆÁ¦ÇÉ°è ¼ö¸éÁ¦
¿À·º½Å ¼ö¿ëü ±æÇ×Á¦
¸á¶óÅä´Ñ ¼ö¿ëü ÀÛ¿ëÁ¦
Å©·Î³ë¼¼¶óÇÇ
Ä¡·á À¯Çüº° ½ÃÀå ¸Å·Âµµ ºÐ¼®
Á¦9Àå ¼¼°èÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå ºÐ¼®°ú ¿¹Ãø, Àå¾Öº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®,2019-2023³â
½ÃÀå ±Ô¸ð(±Ý¾×) ¿¹Ãø, 2024-2031³â
¼ö¸é ´Ü°è ÈÄÅð ÁõÈıº(DSPS)
¼ö¸é»ó ÀüÁø ÁõÈıº(ASPS)
ºñ24½Ã°£ ¼ö¸é°¢¼ºÁõÈıº
ºÒ±ÔÄ¢¼ö¸é°¢¼ºÀå¾Ö(ISWD)
±³´ë±Ù¹« Àå¾Ö
½ÃÂ÷ Àå¾Ö
Àå¾Öº° ½ÃÀå ¸Å·Âµµ ºÐ¼®
Á¦10Àå ¼¼°èÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå ºÐ¼®°ú ¿¹Ãø, À¯Åë ä³Îº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(±Ý¾×) ºÐ¼®,2019-2023³â
½ÃÀå ±Ô¸ð(±Ý¾×) ¿¹Ãø, 2024-2031³â
±â°üÅõÀÚ°¡¿ë ÆÇ¸Å
ÀçÅà Äɾî ȯ°æ
À£´Ï½º ¼¾ÅÍ&½ºÆÄ
¼ö¸é °Ë»ç ¼¾ÅÍ
Àü¹® Ŭ¸®´Ð
º´¿ø
¼Ò¸Å ÆÇ¸Å
¼Ò¸Å ¾à±¹
µå·°½ºÅä¾î
¿Â¶óÀÎ ÆÇ¸Å
À¯Åë ä³Îº° ½ÃÀå ¸Å·Âµµ ºÐ¼®
Á¦11Àå ¼¼°èÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå ºÐ¼®°ú ¿¹Ãø, Áö¿ªº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(±Ý¾×)¿Í ¼ö·® ºÐ¼®,2019-2023³â
½ÃÀå ±Ô¸ð(±Ý¾×)¿Í ¼ö·® ¿¹Ãø, 2024-2031³â
ºÏ¹Ì
¶óƾ¾Æ¸Þ¸®Ä«
À¯·´
³²¾Æ½Ã¾Æ
µ¿¾Æ½Ã¾Æ
¿À¼¼¾Æ´Ï¾Æ
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Áö¿ªº° ½ÃÀå ¸Å·Âµµ ºÐ¼®
Á¦12Àå ºÏ¹ÌÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå ºÐ¼®°ú ¿¹Ãø
Á¦13Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå ºÐ¼®°ú ¿¹Ãø
Á¦14Àå À¯·´ÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå ºÐ¼®°ú ¿¹Ãø
Á¦15Àå µ¿¾Æ½Ã¾ÆÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå ºÐ¼®°ú ¿¹Ãø
Á¦16Àå ³²¾Æ½Ã¾ÆÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå ºÐ¼®°ú ¿¹Ãø
Á¦17Àå ¿À¼¼¾Æ´Ï¾ÆÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå ºÐ¼®°ú ¿¹Ãø
Á¦18Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÏÁֱ⠸®µë ¼ö¸é Ä¡·á ½ÃÀå ºÐ¼®°ú ¿¹Ãø
Á¦19Àå °æÀï ºÐ¼®
°æÀï ´ë½Ãº¸µå
°æÀï¿¡ ÀÇÇÑ °¡°Ý ºÐ¼®
°æÀï º¥Ä¡¸¶Å©
°æÀﺰ ÃÑÀÌÀÍ ºÐ¼®
°æÀï ÁøÀü
°æÀï »ó¼¼
Vanda Pharmaceuticals Inc.
Natus Medical Incorporated
Compumedics Ltd.
Teva Pharmaceutical Industries Ltd
Takeda Pharmaceutical Company
Koninklijke Philips NV
Mylan NV
Fitbit, Inc
Garmin Ltd
Lucimed SA
RedMed Inc.
Compass Health Brands(Carex Health)
Beurer GmbH
Samarit Medical AG
Lanaform NV
Á¦20Àå »ç¿ëµÇ´Â °¡Á¤°ú µÎ¹®ÀÚ¾î
Á¦21Àå Á¶»ç ¹æ¹ý
ksm
¿µ¹® ¸ñÂ÷
The circadian rhythm sleep treatment market is a rapidly evolving sector, driven by increasing awareness about sleep disorders and advancements in sleep medicine. This market encompasses various treatments and therapies designed to address disruptions in the body's internal clock, affecting sleep-wake cycles and overall health. This report delves into the key factors driving growth, potential challenges, and emerging trends in the circadian rhythm sleep treatment market from 2024 through 2031, providing valuable insights for stakeholders and healthcare professionals.
The global circadian rhythm sleep treatment market is expected to experience steady growth during the forecast period, with a projected CAGR of 4.7% from 2024 to 2031. The market is estimated to expand from a value of USD 784 million in 2024 to USD 1.1 billion by the end of 2031.
Key Insights:
Estimated Market Value (2024): USD 784 million
Projected Market Value (2031): USD 1.1 Billion
Global Market Growth Rate (CAGR 2024 to 2031): 4.7%
Circadian Rhythm Sleep Treatment Market - Report Scope:
Circadian rhythm sleep disorders (CRSDs) are becoming more prevalent due to modern lifestyle changes and increased exposure to artificial light, impacting the natural sleep-wake cycle. These disorders include delayed sleep phase disorder (DSPD), advanced sleep phase disorder (ASPD), shift work disorder, and jet lag disorder. The report explores the scope of these treatments, covering various therapies such as light therapy, melatonin supplements, behavioral therapy, and pharmacological approaches.
Market Growth Drivers:
The growth of the circadian rhythm sleep treatment market is driven by several factors. Increasing awareness about the importance of sleep health and its impact on overall well-being is a significant driver. Additionally, the rising prevalence of sleep disorders due to modern lifestyles, stress, and work-related factors fuels the demand for effective treatments. Advances in sleep technology and personalized medicine are enabling more accurate diagnosis and tailored treatment approaches, further boosting market growth. The growing adoption of wearable sleep tracking devices and mobile health applications also contributes to the increased awareness and management of sleep disorders.
Market Restraints:
Despite its growth potential, the circadian rhythm sleep treatment market faces several challenges. High costs associated with some treatments, especially those involving advanced technology or personalized approaches, can deter widespread adoption. Limited access to specialized sleep clinics and professionals in certain regions may also restrict market growth. Additionally, lack of awareness about circadian rhythm disorders among the general population can hinder early diagnosis and treatment. Concerns about the potential side effects of pharmacological treatments and dependency on sleep aids can also affect consumer confidence.
Market Opportunities:
The circadian rhythm sleep treatment market presents numerous opportunities for innovation and expansion. Companies can focus on developing more accessible and affordable treatment options, such as light therapy devices and sleep-tracking wearables. Collaborative efforts between sleep experts and technology companies can lead to more integrated and user-friendly solutions. The rise of telehealth and virtual consultations offers an opportunity to expand access to sleep treatment services, especially in remote areas. Furthermore, increasing public awareness campaigns about sleep health can drive early diagnosis and encourage preventive measures, ultimately contributing to market growth.
Key Questions Addressed in the Report:
What is the Expected Value CAGR of the Circadian Rhythm Sleep Treatment Market?
What is the Revenue Size of the Global Circadian Rhythm Sleep Treatment Market as of 2024-end?
Which Region Held the Largest Market Share in 2024?
Who are the Key Players in the Global Circadian Rhythm Sleep Treatment Market?
What are the Most Effective Treatments for Circadian Rhythm Sleep Disorders?
Competitive Landscape and Business Strategies:
The competitive landscape in the circadian rhythm sleep treatment market features a mix of established pharmaceutical companies and innovative tech startups. Key players like Jazz Pharmaceuticals, Philips Healthcare, and Fitbit offer a range of sleep treatment solutions, from pharmacological therapies to wearable devices. Jazz Pharmaceuticals focuses on developing medications for sleep disorders, including narcolepsy and insomnia. Philips Healthcare offers a variety of sleep-related devices, such as light therapy and continuous positive airway pressure (CPAP) machines. Fitbit, a leader in wearable technology, has integrated sleep tracking features into its fitness devices, enabling users to monitor and improve their sleep patterns.
Key Companies Profiled:
Jazz Pharmaceuticals
Philips Healthcare
Fitbit
ResMed
Takeda Pharmaceuticals
Vanda Pharmaceuticals
Garmin
Zeo Health
Beddit
Casio Computer Co., Ltd.
Medtronic
Circadian Rhythm Sleep Treatment Market Segmentation:
By Treatment Type:
Light Therapy
Melatonin Supplements
Behavioral Therapy
Pharmacological Treatment
By Distribution Channel:
Hospitals and Sleep Clinics
Online Retail
Specialty Pharmacies
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Disorder Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Introduction
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Global Circadian Rhythm Sleep Treatment Market Key Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation Trends
3.3. Innovations & New Launches
3.4. Disease Overview and Epidemiology (Prevalence Data), by Region
4. Global Circadian Rhythm Sleep Treatment Market Key Success Factors
4.1. Product Adoption / Awareness Analysis
4.2. Product Features Vs. Disorder Matrix
5. Global Circadian Rhythm Sleep Treatment Market - Pricing Analysis
5.1. Regional Pricing Analysis
5.2. Pricing Break-Up
5.2.1. Manufacturer Level Pricing
5.2.2. Distributor Level Pricing
5.3. Global Average Pricing Analysis Benchmark
6. Global Circadian Rhythm Sleep Treatment Market Demand Analysis 2019-2023 and Forecast, 2024-2031
6.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
6.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
6.3. Y-o-Y Growth Trend Analysis
7. Global Circadian Rhythm Sleep Treatment Market Context
7.1. Key Regulations
7.2. Macro-Economic Factors
7.3. Forecast Factors - Relevance & Impact
7.4. Market Dynamics
7.4.1. Drivers
7.4.2. Restraints
7.4.3. Opportunity Analysis
8. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Treatment Type
8.1. Introduction/Key Finding
8.1.1. Market Size (US$ Mn) and Volume Share Analysis By Treatment Type
8.1.2. Y-o-Y Growth Analysis By Treatment Type
8.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Treatment Type, 2019-2023
8.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Treatment Type, 2024-2031
8.3.1. Devices
8.3.1.1. Therapeutic Devices
8.3.1.1.1. Light Box
8.3.1.1.2. Desk Lamps
8.3.1.1.3. Light Visor
8.3.1.1.4. Dawn Simulator
8.3.1.2. Diagnostic Devices
8.3.1.2.1. Actigraphy Sensors
8.3.1.2.1.1. Wrist and Hand band Actigraphy Devices
8.3.1.2.1.2. Wearable Actigraphy Devices
8.3.1.2.2. Polysomnography Devices
8.3.1.2.2.1. Fixed Polysomnography Devices
8.3.1.2.2.2. Portable Polysomnography Devices
8.3.2. Drugs
8.3.2.1. Benzodiazepines
8.3.2.2. Nonbenzodiazepine hypnotics
8.3.2.3. Orexin receptor antagonists
8.3.2.4. Melatonin receptor agonist
8.3.3. Chronotherapy
8.4. Market Attractiveness Analysis By Treatment Type
9. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Disorder
9.1. Introduction/Key Finding
9.1.1. Market Size (US$ Mn) Analysis By Disorder
9.1.2. Y-o-Y Growth Analysis By Disorder
9.2. Historical Market Size (US$ Mn) Analysis By Disorder , 2019-2023
9.3. Market Size (US$ Mn) Forecast By Disorder , 2024-2031
9.3.1. Delayed Sleep Phase Syndrome (DSPS)
9.3.2. Advanced Sleep Phase Syndrome (ASPS)
9.3.3. Non-24-h Sleep-Wake Syndrome
9.3.4. Irregular Sleep-Wake Disorder (ISWD)
9.3.5. Shift Work Disorder
9.3.6. Jet Lag
9.4. Market Attractiveness Analysis By Disorder
10. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel
10.1. Introduction/Key Finding
10.1.1. Market Size (US$ Mn) Analysis By Distribution Channel
10.1.2. Y-o-Y Growth Analysis By Distribution Channel
10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
10.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2024-2031
10.3.1. Institutional Sales
10.3.1.1. Home Care Settings
10.3.1.2. Wellness Centers & Spa
10.3.1.3. Sleep Testing Centers
10.3.1.4. Specialty Clinics
10.3.1.5. Hospitals
10.3.2. Retail Sales
10.3.2.1. Retail Pharmacies
10.3.2.2. Drug Stores
10.3.2.3. Online Sales
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031, By Region
11.1. Introduction/Key Finding
11.1.1. Market Size (US$ Mn) and Volume Share Analysis By Region
11.1.2. Y-o-Y Growth Analysis By Region
11.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Region, 2019-2023
11.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Region, 2024-2031
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. South Asia
11.3.5. East Asia
11.3.6. Oceania
11.3.7. Middle East and Africa
11.4. Market Attractiveness Analysis By Region
12. North America Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031
12.1. Introduction
12.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
12.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Treatment Type
12.3.3. By Disorder
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Treatment Type
12.4.3. By Disorder
12.4.4. By Distribution Channel
12.5. Drivers and Restraints: Impact Analysis
12.6. Key Market Participants - Intensity Mapping
13. Latin America Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031
13.1. Introduction
13.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
13.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Mexico
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Treatment Type
13.3.3. By Disorder
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Treatment Type
13.4.3. By Disorder
13.4.4. By Distribution Channel
13.5. Drivers and Restraints: Impact Analysis
13.6. Key Market Participants - Intensity Mapping
14. Europe Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031
14.1. Introduction
14.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
14.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
14.3.1. By Country
14.3.1.1. U.K.
14.3.1.2. Germany
14.3.1.3. France
14.3.1.4. Italy
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Nordic
14.3.1.8. Poland
14.3.1.9. Rest of Europe
14.3.2. By Treatment Type
14.3.3. By Disorder
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Treatment Type
14.4.3. By Disorder
14.4.4. By Distribution Channel
14.5. Drivers and Restraints: Impact Analysis
14.6. Key Market Participants - Intensity Mapping
15. East-Asia Circadian Rhythm Sleep Treatment Market Analysis 2019-2023 and Forecast 2024-2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
15.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.1.4. Rest of East Asia
15.3.2. By Treatment Type
15.3.3. By Disorder
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Treatment Type
15.4.3. By Disorder
15.4.4. By Distribution Channel
15.5. Drivers and Restraints: Impact Analysis
15.6. Key Market Participants - Intensity Mapping
16. South Asia Circadian Rhythm Sleep Treatment Market Analysis and Forecast 2019-2023 and Forecast 2024-2031
16.1. Introduction
16.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
16.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Thailand
16.3.1.3. Malaysia
16.3.1.4. Indonesia
16.3.1.5. Philippines
16.3.1.6. Rest of South Asia
16.3.2. By Treatment Type
16.3.3. By Disorder
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Treatment Type
16.4.3. By Disorder
16.4.4. By Distribution Channel
16.5. Drivers and Restraints: Impact Analysis
16.6. Key Market Participants - Intensity Mapping
17. Oceania Circadian Rhythm Sleep Treatment Market Analysis and Forecast 2019-2023 and Forecast 2024-2031
17.1. Introduction
17.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
17.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Treatment Type
17.3.3. By Disorder
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Treatment Type
17.4.3. By Disorder
17.4.4. By Distribution Channel
17.5. Drivers and Restraints: Impact Analysis
17.6. Key Market Participants - Intensity Mapping
18. MEA Circadian Rhythm Sleep Treatment Market Analysis and Forecast 2019-2023 and Forecast 2024-2031
18.1. Introduction
18.2. Historical Market Size (US$ Mn) and Volume (US$ Mn) Analysis By Market Segments, 2019-2023
18.3. Market Size (US$ Mn) and Volume (US$ Mn) Forecast By Market Segments, 2024-2031
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Iran
18.3.1.3. Israel
18.3.1.4. Turkey
18.3.1.5. Rest of MEA
18.3.2. By Treatment Type
18.3.3. By Disorder
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Treatment Type
18.4.3. By Disorder
18.4.4. By Distribution Channel
18.5. Drivers and Restraints: Impact Analysis
18.6. Key Market Participants - Intensity Mapping
19. Competition Analysis
19.1. Competition Dashboard
19.2. Pricing Analysis, By Competition
19.3. Competition Benchmarking
19.4. Gross Margin Analysis, By Competition
19.5. Competition Developments
19.6. Competition Deep Dive
19.6.1. Vanda Pharmaceuticals Inc.
19.6.1.1. Overview
19.6.1.2. Product and Disorder Portfolio
19.6.1.3. Production Footprint
19.6.1.4. Sales Footprint
19.6.1.5. Strategy
19.6.1.5.1. Marketing Strategy
19.6.1.5.2. Product Strategy
19.6.1.5.3. Channel Strategy
19.6.2. Natus Medical Incorporated
19.6.2.1. Overview
19.6.2.2. Product and Disorder Portfolio
19.6.2.3. Production Footprint
19.6.2.4. Sales Footprint
19.6.2.5. Strategy
19.6.2.5.1. Marketing Strategy
19.6.2.5.2. Product Strategy
19.6.2.5.3. Channel Strategy
19.6.3. Compumedics Ltd.
19.6.3.1. Overview
19.6.3.2. Product and Disorder Portfolio
19.6.3.3. Production Footprint
19.6.3.4. Sales Footprint
19.6.3.5. Strategy
19.6.3.5.1. Marketing Strategy
19.6.3.5.2. Product Strategy
19.6.3.5.3. Channel Strategy
19.6.4. Teva Pharmaceutical Industries Ltd
19.6.4.1. Overview
19.6.4.2. Product and Disorder Portfolio
19.6.4.3. Production Footprint
19.6.4.4. Sales Footprint
19.6.4.5. Strategy
19.6.4.5.1. Marketing Strategy
19.6.4.5.2. Product Strategy
19.6.4.5.3. Channel Strategy
19.6.5. Takeda Pharmaceutical Company
19.6.5.1. Overview
19.6.5.2. Product and Disorder Portfolio
19.6.5.3. Production Footprint
19.6.5.4. Sales Footprint
19.6.5.5. Strategy
19.6.5.5.1. Marketing Strategy
19.6.5.5.2. Product Strategy
19.6.5.5.3. Channel Strategy
19.6.6. Koninklijke Philips N.V
19.6.6.1. Overview
19.6.6.2. Product and Disorder Portfolio
19.6.6.3. Production Footprint
19.6.6.4. Sales Footprint
19.6.6.5. Strategy
19.6.6.5.1. Marketing Strategy
19.6.6.5.2. Product Strategy
19.6.6.5.3. Channel Strategy
19.6.7. Mylan N.V
19.6.7.1. Overview
19.6.7.2. Product and Disorder Portfolio
19.6.7.3. Production Footprint
19.6.7.4. Sales Footprint
19.6.7.5. Strategy
19.6.7.5.1. Marketing Strategy
19.6.7.5.2. Product Strategy
19.6.7.5.3. Channel Strategy
19.6.8. Fitbit, Inc
19.6.8.1. Overview
19.6.8.2. Product and Disorder Portfolio
19.6.8.3. Production Footprint
19.6.8.4. Sales Footprint
19.6.8.5. Strategy
19.6.8.5.1. Marketing Strategy
19.6.8.5.2. Product Strategy
19.6.8.5.3. Channel Strategy
19.6.9. Garmin Ltd
19.6.9.1. Overview
19.6.9.2. Product and Disorder Portfolio
19.6.9.3. Production Footprint
19.6.9.4. Sales Footprint
19.6.9.5. Strategy
19.6.9.5.1. Marketing Strategy
19.6.9.5.2. Product Strategy
19.6.9.5.3. Channel Strategy
19.6.10. Lucimed S.A.
19.6.10.1. Overview
19.6.10.2. Product and Disorder Portfolio
19.6.10.3. Production Footprint
19.6.10.4. Sales Footprint
19.6.10.5. Strategy
19.6.10.5.1. Marketing Strategy
19.6.10.5.2. Product Strategy
19.6.10.5.3. Channel Strategy
19.6.11. RedMed Inc.
19.6.11.1. Overview
19.6.11.2. Product and Disorder Portfolio
19.6.11.3. Production Footprint
19.6.11.4. Sales Footprint
19.6.11.5. Strategy
19.6.11.5.1. Marketing Strategy
19.6.11.5.2. Product Strategy
19.6.11.5.3. Channel Strategy
19.6.12. Compass Health Brands (Carex Health)
19.6.12.1. Overview
19.6.12.2. Product and Disorder Portfolio
19.6.12.3. Production Footprint
19.6.12.4. Sales Footprint
19.6.12.5. Strategy
19.6.12.5.1. Marketing Strategy
19.6.12.5.2. Product Strategy
19.6.12.5.3. Channel Strategy
19.6.13. Beurer GmbH
19.6.13.1. Overview
19.6.13.2. Product and Disorder Portfolio
19.6.13.3. Production Footprint
19.6.13.4. Sales Footprint
19.6.13.5. Strategy
19.6.13.5.1. Marketing Strategy
19.6.13.5.2. Product Strategy
19.6.13.5.3. Channel Strategy
19.6.14. Samarit Medical AG
19.6.14.1. Overview
19.6.14.2. Product and Disorder Portfolio
19.6.14.3. Production Footprint
19.6.14.4. Sales Footprint
19.6.14.5. Strategy
19.6.14.5.1. Marketing Strategy
19.6.14.5.2. Product Strategy
19.6.14.5.3. Channel Strategy
19.6.15. Lanaform N.V.
19.6.15.1. Overview
19.6.15.2. Product and Disorder Portfolio
19.6.15.3. Production Footprint
19.6.15.4. Sales Footprint
19.6.15.5. Strategy
19.6.15.5.1. Marketing Strategy
19.6.15.5.2. Product Strategy
19.6.15.5.3. Channel Strategy
20. Assumptions and Acronyms Used
21. Research Methodology
°ü·ÃÀÚ·á